Title |
Elotuzumab for the treatment of multiple myeloma
|
---|---|
Published in |
Journal of Hematology & Oncology, July 2016
|
DOI | 10.1186/s13045-016-0284-z |
Pubmed ID | |
Authors |
Yucai Wang, Larysa Sanchez, David S. Siegel, Michael L. Wang |
Abstract |
Elotuzumab is one of the first two monoclonal antibodies that gained FDA approval for the treatment of multiple myeloma (MM). It targets SLAMF7, which is highly expressed in normal plasma and MM cells as well as natural killer (NK) cells. Elotuzumab demonstrated significant anti-myeloma activity in preclinical studies, and its mechanisms of action include mediating antibody-dependent cell-mediated cytotoxicity, enhancing cytotoxicity of NK cells, and inhibiting MM cell interaction with bone marrow stromal cells. In clinical trials, elotuzumab in combination with immunomodulatory drugs and proteasome inhibitors has demonstrated an excellent efficacy and safety profile in treating MM. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 29% |
Mexico | 1 | 14% |
India | 1 | 14% |
Unknown | 3 | 43% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 71% |
Scientists | 2 | 29% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 48 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 7 | 15% |
Student > Master | 5 | 10% |
Other | 4 | 8% |
Student > Postgraduate | 3 | 6% |
Researcher | 3 | 6% |
Other | 6 | 13% |
Unknown | 20 | 42% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 12 | 25% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 8% |
Biochemistry, Genetics and Molecular Biology | 3 | 6% |
Immunology and Microbiology | 3 | 6% |
Nursing and Health Professions | 2 | 4% |
Other | 2 | 4% |
Unknown | 22 | 46% |